📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype (2020)

First Author: Lu C

Attributed to: BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2020.04.473

PubMed Identifier: 32387417

Publication URI: http://europepmc.org/abstract/MED/32387417

Type: Journal Article/Review

Parent Publication: Annals of Oncology

Issue: 9

ISSN: 0923-7534